Nuvectis Pharma Stock (NASDAQ:NVCT)
Previous Close
$4.69
52W Range
$4.44 - $12.10
50D Avg
$6.46
200D Avg
$6.83
Market Cap
$87.33M
Avg Vol (3M)
$173.02K
Beta
0.40
Div Yield
-
NVCT Company Profile
Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. It develops NXP800, a novel heat shock factor 1 pathway inhibitor for the treatment of various cancers; and NXP900, a small molecule drug candidate to inhibit the Proto-oncogene c-Src and YES1 kinases. The company was incorporated in 2020 and is based in Fort Lee, New Jersey.
NVCT Performance
Peer Comparison
Ticker | Company |
---|---|
CGEM | Cullinan Oncology, Inc. |
CNTA | Centessa Pharmaceuticals plc |
AVTE | Aerovate Therapeutics, Inc. |
OBIO | Orchestra BioMed Holdings, Inc. |
REPL | Replimune Group, Inc. |
KRON | Kronos Bio, Inc. |
OLMA | Olema Pharmaceuticals, Inc. |
GOSS | Gossamer Bio, Inc. |
IVA | Inventiva S.A. |
IKNA | Ikena Oncology, Inc. |
LRMR | Larimar Therapeutics, Inc. |
EWTX | Edgewise Therapeutics, Inc. |
CCCC | C4 Therapeutics, Inc. |
GLUE | Monte Rosa Therapeutics, Inc. |
HOWL | Werewolf Therapeutics, Inc. |
ANEB | Anebulo Pharmaceuticals, Inc. |
CMPX | Compass Therapeutics, Inc. |
NAMS | NewAmsterdam Pharma Company N.V. |
LYRA | Lyra Therapeutics, Inc. |
CELC | Celcuity Inc. |